359 related articles for article (PubMed ID: 34207685)
1. Drug Resistance in Osteosarcoma: Emerging Biomarkers, Therapeutic Targets and Treatment Strategies.
Hattinger CM; Patrizio MP; Fantoni L; Casotti C; Riganti C; Serra M
Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34207685
[TBL] [Abstract][Full Text] [Related]
2. An update on emerging drugs in osteosarcoma: towards tailored therapies?
Hattinger CM; Patrizio MP; Magagnoli F; Luppi S; Serra M
Expert Opin Emerg Drugs; 2019 Sep; 24(3):153-171. PubMed ID: 31401903
[No Abstract] [Full Text] [Related]
3. Candidate germline polymorphisms of genes belonging to the pathways of four drugs used in osteosarcoma standard chemotherapy associated with risk, survival and toxicity in non-metastatic high-grade osteosarcoma.
Hattinger CM; Biason P; Iacoboni E; Gagno S; Fanelli M; Tavanti E; Vella S; Ferrari S; Roli A; Roncato R; Giodini L; Scotlandi K; Picci P; Toffoli G; Serra M
Oncotarget; 2016 Sep; 7(38):61970-61987. PubMed ID: 27566557
[TBL] [Abstract][Full Text] [Related]
4. Strategies to Overcome Resistance to Immune-Based Therapies in Osteosarcoma.
Hattinger CM; Salaroglio IC; Fantoni L; Godel M; Casotti C; Kopecka J; Scotlandi K; Ibrahim T; Riganti C; Serra M
Int J Mol Sci; 2023 Jan; 24(1):. PubMed ID: 36614241
[TBL] [Abstract][Full Text] [Related]
5. Pharmacogenomics of second-line drugs used for treatment of unresponsive or relapsed osteosarcoma patients.
Hattinger CM; Vella S; Tavanti E; Fanelli M; Picci P; Serra M
Pharmacogenomics; 2016 Dec; 17(18):2097-2114. PubMed ID: 27883291
[TBL] [Abstract][Full Text] [Related]
6. Targeting aggressive osteosarcoma with a peptidase-enhanced cytotoxic melphalan flufenamide.
Byrgazov K; Anderson C; Salzer B; Bozsaky E; Larsson R; Gullbo J; Lehner M; Lehmann F; Slipicevic A; Kager L; Fryknäs M; Taschner-Mandl S
Ther Adv Med Oncol; 2020; 12():1758835920937891. PubMed ID: 32774473
[TBL] [Abstract][Full Text] [Related]
7. Current understanding of pharmacogenetic implications of DNA damaging drugs used in osteosarcoma treatment.
Hattinger CM; Patrizio MP; Luppi S; Magagnoli F; Picci P; Serra M
Expert Opin Drug Metab Toxicol; 2019 Apr; 15(4):299-311. PubMed ID: 30822170
[TBL] [Abstract][Full Text] [Related]
8. Pharmacogenomics and Pharmacogenetics in Osteosarcoma: Translational Studies and Clinical Impact.
Hattinger CM; Patrizio MP; Luppi S; Serra M
Int J Mol Sci; 2020 Jun; 21(13):. PubMed ID: 32629971
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenomics of genes involved in antifolate drug response and toxicity in osteosarcoma.
Hattinger CM; Tavanti E; Fanelli M; Vella S; Picci P; Serra M
Expert Opin Drug Metab Toxicol; 2017 Mar; 13(3):245-257. PubMed ID: 27758143
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular recurrence of high-grade osteosarcoma presenting as atrial thrombosis and pulmonary embolism: A case report and review of the pediatric literature.
Ting M; Rodriguez M; Gowda ST; Anders M; Qureshi AM; Grimes A
Pediatr Hematol Oncol; 2019 May; 36(4):244-251. PubMed ID: 31179809
[TBL] [Abstract][Full Text] [Related]
11. Cisplatin Resistance in Osteosarcoma:
Fanelli M; Tavanti E; Patrizio MP; Vella S; Fernandez-Ramos A; Magagnoli F; Luppi S; Hattinger CM; Serra M
Front Oncol; 2020; 10():331. PubMed ID: 32211337
[TBL] [Abstract][Full Text] [Related]
12. Can pharmacogenomics help to improve therapy in patients with high-grade osteosarcoma?
Kager L; Diakos C; Bielack S
Expert Opin Drug Metab Toxicol; 2015 Jul; 11(7):1025-8. PubMed ID: 25882838
[TBL] [Abstract][Full Text] [Related]
13. Targeting Clusterin Induces Apoptosis, Reduces Growth Ability and Invasion and Mediates Sensitivity to Chemotherapy in Human Osteosarcoma Cells.
Wang X; Yu Y; Zang L; Zhang P; Ma J; Chen D
Curr Pharm Biotechnol; 2020; 21(2):131-139. PubMed ID: 31433751
[TBL] [Abstract][Full Text] [Related]
14. Genetic testing for high-grade osteosarcoma: a guide for future tailored treatments?
Hattinger CM; Patrizio MP; Tavanti E; Luppi S; Magagnoli F; Picci P; Serra M
Expert Rev Mol Diagn; 2018 Nov; 18(11):947-961. PubMed ID: 30324828
[TBL] [Abstract][Full Text] [Related]
15. Advances in emerging drugs for osteosarcoma.
Hattinger CM; Fanelli M; Tavanti E; Vella S; Ferrari S; Picci P; Serra M
Expert Opin Emerg Drugs; 2015 Sep; 20(3):495-514. PubMed ID: 26021401
[TBL] [Abstract][Full Text] [Related]
16. Drug resistance-related microRNAs in osteosarcoma: Translating basic evidence into therapeutic strategies.
Chen R; Wang G; Zheng Y; Hua Y; Cai Z
J Cell Mol Med; 2019 Apr; 23(4):2280-2292. PubMed ID: 30724027
[TBL] [Abstract][Full Text] [Related]
17. Targeting Molecular Mechanisms Underlying Treatment Efficacy and Resistance in Osteosarcoma: A Review of Current and Future Strategies.
Lilienthal I; Herold N
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32961800
[TBL] [Abstract][Full Text] [Related]
18. Recent Advances in the Discovery of Biomarkers for Canine Osteosarcoma.
Luu AK; Wood GA; Viloria-Petit AM
Front Vet Sci; 2021; 8():734965. PubMed ID: 34660770
[TBL] [Abstract][Full Text] [Related]
19. Intrinsic resistance to chemotherapeutic agents in murine osteosarcoma cells.
Takeshita H; Kusuzaki K; Ashihara T; Gebhardt MC; Mankin HJ; Hirasawa Y
J Bone Joint Surg Am; 2000 Jul; 82-A(7):963-9. PubMed ID: 10901311
[TBL] [Abstract][Full Text] [Related]
20. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
